We further evaluated whether pan-FGFR kinase inhibitors, BGJ398 and ponatinib, could represent a potential therapeutic strategy for patients with FGFR3–TACC3 NSCLC. In particular, BGJ398 is a selective FGFR inhibitor while ponatinib is a multitargeted agent with FGFR activity. Both BGJ398 and ponatinib, but not the EGFR kinase inhibitor gefitinib, effectively inhibited the growth of the FGFR3–TACC3 Ba/F3 cells